| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Evaxion Biotech A/S (NASDAQ: EVAX)
EVAX Technical Analysis
5
| As on 9th Jun 2023 EVAX STOCK Price closed @ 1.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.75 & Strong Sell for SHORT-TERM with Stoploss of 3.60 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EVAXSTOCK Price
| Open | 1.39 | Change | Price | % |
| High | 1.39 | 1 Day | -0.08 | -5.80 |
| Low | 1.26 | 1 Week | -0.22 | -14.47 |
| Close | 1.30 | 1 Month | 0.02 | 1.56 |
| Volume | 151874 | 1 Year | -2.82 | -68.45 |
| 52 Week High 4.65 | 52 Week Low 1.03 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| EVAX Daily Charts |
EVAX Intraday Charts |
Whats New @ Bazaartrend |
EVAX Free Analysis |
|
|
EVAX Important Levels Intraday
| RESISTANCE | 1.55 |
| RESISTANCE | 1.47 |
| RESISTANCE | 1.42 |
| RESISTANCE | 1.37 |
| SUPPORT | 1.23 |
| SUPPORT | 1.18 |
| SUPPORT | 1.13 |
| SUPPORT | 1.05 |
EVAX Forecast May 2024
| 4th UP Forecast | 4.9 |
| 3rd UP Forecast | 3.75 |
| 2nd UP Forecast | 3.03 |
| 1st UP Forecast | 2.32 |
| 1st DOWN Forecast | 0.28 |
| 2nd DOWN Forecast | -0.43 |
| 3rd DOWN Forecast | -1.15 |
| 4th DOWN Forecast | -2.3 |
EVAX Weekly Forecast
| 4th UP Forecast | 2.59 |
| 3rd UP Forecast | 2.18 |
| 2nd UP Forecast | 1.92 |
| 1st UP Forecast | 1.67 |
| 1st DOWN Forecast | 0.93 |
| 2nd DOWN Forecast | 0.68 |
| 3rd DOWN Forecast | 0.42 |
| 4th DOWN Forecast | 0.01 |
EVAX Forecast2024
| 4th UP Forecast | 8.55 |
| 3rd UP Forecast | 6.22 |
| 2nd UP Forecast | 4.79 |
| 1st UP Forecast | 3.35 |
| 1st DOWN Forecast | -0.75 |
| 2nd DOWN Forecast | -2.19 |
| 3rd DOWN Forecast | -3.62 |
| 4th DOWN Forecast | -5.95 |
Evaxion Biotech A/S ( NASDAQ USA Symbol : EVAX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EVAX Business Profile
Evaxion Biotech A/S, a clinical-stage artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase I/IIa trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark. Address: Dr. Neergaards Vej 5f DK, Hoersholm, Denmark, 2970
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service